Beyond Biotech podcast 53: Drug-antibody conjugates
On this week’s podcast, we discuss drug-antibody conjugates with Pejvack Motlagh, who was recently announced as chief medical officer at Mablink Bioscience.
Mablink Biosciences
Mablink Bioscience is a biotechnology company developing the next generation of a new class of cancer drugs, drug-antibody conjugates (ADCs).
Mablink’s patented hydrophilic drug binder technology, PSARLink, enables the design of next-generation homogeneous, plasma-stable ADCs with a high DAR (drug-to-antibody ratio) while maintaining pharmacological properties and tolerability.
The company recently announced the appointment of Dr. Pejvack Motlagh as chief medical officer.
“We are very pleased to welcome Dr. Pejvack Motlagh as our chief medical officer. His experience in managing the oncology portfolio, especially in the immuno-oncology and large molecular space, will be a huge asset to take Mablink’s innovative therapeutic range to the next level,” said Jean-Guillaume Lafay, CEO of Mablink.
“As MBK-103 enters its final preclinical phase, Pejvack’s appointment is a very important step in realizing Mablink’s clinical ambitions.”
We spoke to Motlagh about his work, Mablink, and drug-antibody conjugation.
